Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. APLM
stocks logo

APLM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for Apollomics Inc (APLM.O) is -0.17, compared to its 5-year average forward P/E of -4.38. For a more detailed relative valuation and DCF analysis to assess Apollomics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.38
Current PE
-0.17
Overvalued PE
1.46
Undervalued PE
-10.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.85
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.15
Undervalued EV/EBITDA
-9.85

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
31.81
Current PS
0.00
Overvalued PS
146.91
Undervalued PS
-83.29
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

APLM News & Events

Events Timeline

(ET)
2025-11-19
17:41:31
Apollomics reveals resolution of legal dispute in the Cayman Islands
select
2025-10-15 (ET)
2025-10-15
14:44:31
Apollomics Announces Continued Nasdaq Listing for Securities
select
2025-10-14 (ET)
2025-10-14
16:08:24
Nasdaq Restarts Trading for Apollomics
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-18Yahoo Finance
Apollomics Reveals Updates to Board of Directors and Committee Structure

  • Board Changes: Apollomics Inc. announced the resignation of Mr. Po-Jen Hsueh from its board, with Dr. Ya-Chi (Claudia) Huang appointed to fill the vacancy and join the Audit and Nominating Committees.

  • New Director's Background: Dr. Huang has extensive experience in biotechnology investment and corporate governance, currently serving as Assistant Vice President at Maxpro Ventures and previously as Investment Manager at Diamond Biofund.

  • Company Focus: Apollomics is a clinical-stage biopharmaceutical company specializing in oncology therapies, with its lead program, vebreltinib, currently in a Phase 2 clinical trial for non-small cell lung cancer.

  • Forward-Looking Statements: The press release includes forward-looking statements regarding Apollomics' strategies and anticipated outcomes, cautioning that these are subject to risks and uncertainties.

[object Object]
Preview
9.5
11-03Benzinga
Lucas GC Shares Surge Over 36%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Lucas GC Limited Financial Results: Lucas GC Limited's shares surged 36.2% to $3.73 in pre-market trading after reporting H1 2025 earnings per share (EPS) of $1.47 on sales of $54.008 million.

  • Other Notable Gainers: MSP Recovery, Inc. saw a dramatic 262% increase to $0.7706, while SMX (Security Matters) Public Limited Company rose 72% to $3.47, among other significant pre-market gains.

  • Stocks Experiencing Losses: ZOOZ Strategy Ltd. dropped 28.3% to $1.01, and Alvotech fell 21.6% to $6.00, reflecting a trend of declines in several stocks after previous gains.

  • Market Overview: The pre-market trading session showed a mix of significant gains and losses across various stocks, indicating volatility in the market following recent trading activities.

[object Object]
Preview
7.0
10-16Newsfilter
Apollomics Confirms Ongoing Nasdaq Listing After Hearing Cancellation

  • Nasdaq Compliance: Apollomics Inc. has received confirmation from Nasdaq that it is in compliance with listing requirements, leading to the cancellation of its appeal hearing regarding a previous delisting notification.

  • Company Overview: Apollomics is a clinical-stage biopharmaceutical company focused on developing oncology therapies, with its lead drug candidate, vebreltinib, currently in Phase 2 trials for treating non-small cell lung cancer and other advanced tumors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Apollomics Inc (APLM) stock price today?

The current price of APLM is 14.745 USD — it has increased 6.54 % in the last trading day.

arrow icon

What is Apollomics Inc (APLM)'s business?

Apollomics Inc. is a clinical-stage biopharmaceutical company focusing on discovering and developing oncology therapies to address unmet medical needs, especially for difficult-to-treat and treatment-resistant cancers. The product candidates in its pipeline are categorized into two groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumor inhibitors and immuno-oncology drugs. Its tumor inhibitor product candidates consist of three small-molecule inhibitors against different uncontrolled growth signaling pathways in cancer cells: vebreltinib, APL-102 and APL-122. Its three immuno-oncology product candidates consist of APL-501, APL-502 and APL-80. Vebreltinib is a potent, oral active selective c-Met inhibitor. APL-102 is an oral active, small molecule Multiple Tyrosine Kinase Inhibitor. APL-122 is a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways. APL-501 is an anti-PD-1 antibody product candidate.

arrow icon

What is the price predicton of APLM Stock?

Wall Street analysts forecast APLM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for APLM is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Apollomics Inc (APLM)'s revenue for the last quarter?

Apollomics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Apollomics Inc (APLM)'s earnings per share (EPS) for the last quarter?

Apollomics Inc. EPS for the last quarter amounts to -0.00 USD, decreased -100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Apollomics Inc (APLM)'s fundamentals?

The market is revising No Change the revenue expectations for Apollomics, Inc. (APLM) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 185.76%.
arrow icon

How many employees does Apollomics Inc (APLM). have?

Apollomics Inc (APLM) has 13 emplpoyees as of December 05 2025.

arrow icon

What is Apollomics Inc (APLM) market cap?

Today APLM has the market capitalization of 31.60M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free